Navigation Links
Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
Date:8/21/2008

com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
2. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
3. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
4. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
7. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
8. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
9. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
10. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Colo. , June 1 Encision Inc. (OTC ... technology that is emerging as a standard of care in ... purchasing agreement with HealthTrust Purchasing Group, LP ("HealthTrust"), effective ... are "Laparoscopic Safety Instruments – Active Electrode Monitoring Laparoscopy". , ...
... DURECT Corporation (Nasdaq: DRRX ) announced today that James E. Brown , ... Conference on Thursday, June 10 at 10:30 a.m. Eastern Time . ... .   , , , ... , , ...
Cached Medicine Technology:Encision and HealthTrust Purchasing Group Sign Purchasing Agreement 2DURECT to Present at the Jefferies Global Life Sciences Conference 2
(Date:9/21/2014)... Huntington, New York (PRWEB) September 21, 2014 ... release of their Risk Management Portal designed for ... applications with the intent to support effective risk ... is scheduled to go live coinciding with Waldorf’s ... September 21-24, 2014. , These applications were developed ...
(Date:9/21/2014)... September 21, 2014 "I wanted to ... having to consume sugary, foul-tasting energy drinks," said an ... always just want to drink plain, old coffee. That ... booster." , He developed ENERG CHEWING GUM to provide ... weight loss. The formula contains nutritious vitamins, minerals and ...
(Date:9/21/2014)... of Sparta. , Ancient Greek warriors were fed a ... of battle on distant fields. Cancer cells that metastasize ... study revealing previously unknown differences between cancer cells that ... those that travel to other organs. , Given that ... primary cause of cancer-related death, understanding how they successfully ...
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... September 21, 2014 The Electronic ... and supports electronic medical records (EMR) and electronic ... federal healthcare legislation during the past five years ... during the five years to 2019. The 2009 ... Act established Medicare and Medicaid incentives to encourage ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Cancer cells adapt energy needs to spread illness to other organs 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Electronic Medical Records Systems in the US Industry Market Research Report Now Available from IBISWorld 4
... Electronic devices of the future could be smaller, faster, ... discovery by researchers at the Department of Energy,s Oak ... published in Science , involves a method to ... decades have held tremendous promise but have eluded experimental ...
... 17 HealthTronics, Inc. ("HealthTronics") (Nasdaq: HTRN ... ) announced today that HealthTronics has commenced an exchange ... common stock pursuant to their previously-announced definitive agreement dated ... of the exchange offer, Endocare stockholders who validly tender ...
... Inclusion of General Surgeons, Otolaryngologists and , Ophthalmologists ... The American College of Surgeons (ACS) supports legislation ... Zack Space (D-Ohio), which includes the participation of general ... Loan Repayment Program called the Access to Frontline Health ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that it ... June 24 in Boston, Massachusetts. , , A live webcast ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... of the webcast will be available for 30 days after the ...
... ... Center, the most comprehensive program in Orange County. Hoag Voice and Swallowing Center provides ... , ... CA (Vocus) June 17, 2009 -- Hoag Hospital announces the grand opening of ...
... Health-privacy advocates and patient-choice supporters will discuss implications of federal ... on Thursday, June 18 at 9:00 am. Health-policy experts will ... HEALTH-PRIVACY RIGHTS: Which bills will make sure Americans are not ... and track them from cradle to grave and that citizens ...
Cached Medicine News:Health News:ORNL finding could help electronics industry enter new phase 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 3Health News:American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 3
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Dual offset femoral stems, hip stems that provide unique and competitive features....
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
Medicine Products: